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ABSTRACT: Adaptor protein Grb2 binds phosphotyrosines in the epidermal growth
factor (EGF) receptor (EGFR) and thereby links receptor activation to intracellular
signaling cascades. Here, we investigated how recruitment of Grb2 to EGFR is affected
by the spatial organization and quaternary state of activated EGFR. We used the
techniques of image correlation spectroscopy (ICS) and lifetime-detected Förster
resonance energy transfer (also known as FLIM-based FRET or FLIM−FRET) to
measure ligand-induced receptor clustering and Grb2 binding to activated EGFR in
BaF/3 cells. BaF/3 cells were stably transfected with fluorescently labeled forms of
Grb2 (Grb2−mRFP) and EGFR (EGFR−eGFP). Following stimulation of the cells
with EGF, we detected nanometer-scale association of Grb2−mRFP with EGFR−
eGFP clusters, which contained, on average, 4 ± 1 copies of EGFR−eGFP per cluster.
In contrast, the pool of EGFR−eGFP without Grb2−mRFP had an average cluster size of 1 ± 0.3 EGFR molecules per punctum.
In the absence of EGF, there was no association between EGFR−eGFP and Grb2−mRFP. To interpret these data, we extended
our recently developed model for EGFR activation, which considers EGFR oligomerization up to tetramers, to include
recruitment of Grb2 to phosphorylated EGFR. The extended model, with adjustment of one new parameter (the ratio of the
Grb2 and EGFR copy numbers), is consistent with a cluster size distribution where 2% of EGFR monomers, 5% of EGFR
dimers, <1% of EGFR trimers, and 94% of EGFR tetramers are associated with Grb2. Together, our experimental and modeling
results further implicate tetrameric EGFR as the key signaling unit and call into question the widely held view that dimeric EGFR
is the predominant signaling unit.
The epidermal growth factor (EGF) receptor (EGFR) is amember of the ErbB family of receptor tyrosine kinases.1,2
The EGFR signaling network contributes to a number of
processes important to cancer development and progression,
including cell proliferation, angiogenesis, and metastatic spread.
EGFR overexpression and truncation3 have been observed in a
number of common cancers, including brain, lung, breast,
colon, and prostate, giving credence to the notion that a
molecular understanding of EGFR activation will yield clinical
benefit. EGFR signaling is generally regarded to be initiated by
ligand binding to the extracellular region, which leads to
receptor dimerization,4 conformational rearrangements within
preformed complexes5−7 and higher-order oligomerization8−10.
Subsequent to kinase activation and autophosphorylation,
cytoplasmic adaptors are recruited to the EGFR cytoplasmic
tail.11−16 Whether these processes are influenced by the size of
the EGFR cell-surface clusters is an important question. Here,
we address this question with a focus on adaptor binding, which
is the first step after receptor activation and connects receptor
activation to its intracellular signaling cascades.
Grb2 is a pivotal adaptor first discovered to physically link
phosphorylated EGFR to the Ras signaling pathway11,12
through the guanine nucleotide exchange factor Sos.13 Grb2
overexpression has been found in breast cancer cells.14 Since
the initial discovery, Grb2 has been linked to a host of other
cellular pathways including the actin cytoskeleton and
endocytosis.15
Theoretical studies suggest the possibility that EGFR
clustering into subcellular domains (or perhaps protein islands)
may indeed influence the binding of cytoplasmic adaptors such
as Grb2.16 Comparison of randomly dispersed EGFR dimers
and clustered EGFR distributions predicted the retention of
EGFR−Grb2 complexes in clusters for a longer period than the
randomly distributed dimeric EGFR distributions. Conse-
quently, it is important to measure the cluster size of
adaptor-bound EGFR and to determine whether there is a
relationship between adaptor binding and receptor cluster size.
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We have made use of a method developed in our earlier work
to determine the relative cluster size of complexed versus
uncomplexed molecules on the surface of cells.9 The method,
called FRET−FLIM−ICS,17 combines two well-established
techniques: (1) lifetime-detected (FLIM) FRET,18 which can
be used to measure complex formation, and (2) image
correlation spectroscopy (ICS),19−23 which can be used to
determine cluster densities and sizes. Sorkin and co-workers
previously established that FRET can be used to detect
interactions between EGFR and Grb2, but no estimates of
cluster sizes were made in that study.32
To ascertain the relative importance of dimers versus higher-
order oligomers, one requires a model system wherein higher-
order oligomerization has been established and characterized.
Such a system is provided by murine BaF/3 cells stably
transfected with EGFR coupled at the C-terminus to an
enhanced GFP tag (EGFR−eGFP). In prior work with this
system, we found that EGFR−eGFP is predominantly dimeric
in the absence of ligand (with less than 10% of EGFR−eGFP
being monomeric) and forms phosphorylated tetramers upon
exposure to ligand.8,24,25 The results reported here were
obtained using two related BaF/3 cell lines: the cell line used
in prior work,8 which expresses EGFR−eGFP at physiological
levels (i.e., 50 000 to 70 000 copies per cell), and a new cell line
expressing both EGFR−eGFP and Grb2−mRFP.
Our report is organized as follows. First, we present FLIM
data for EGFR−eGFP BaF/3 cells and EGFR−eGFP/Grb2−
mRFP BaF/3 cells with different combinations of EGF
stimulation. Using the cell-phasor approach to lifetime
microscopy,26−29 we detected EGF-dependent FRET between
EGFR−eGFP and Grb2−mRFP. Second, we present the results
of FRET−FLIM−ICS analysis of individual EGFR−eGFP/
Grb2−mRFP BaF/3 cells. The results indicate that Grb2−
mRFP associated with EGF-EGFR−eGFP complexes that are
more than 4-fold brighter than EGF-EGFR−eGFP complexes
not associated with Grb2−mRFP. The brightness ratio, as well
as Grb2−mRFP association with EGFR−eGFP, correlates
positively with EGFR−eGFP cluster density. Third, we present
a rule-based model, which we have used to interpret our
experimental data. The model is an extension of our earlier
model25 and now includes EGFR−Grb2 binding in addition to
the processes considered in the original model (i.e., ligand−
receptor binding, self-interactions capable of mediating receptor
oligomerization, and receptor autophosphorylation). In the
extended model, receptors are considered to be bivalent, with
sites of self-interaction in the ectodomain and the cytoplasmic
domain. The model allows for the formation of extended
polymer-like chains (up to tetramers) as well as the formation
of a cyclic receptor tetramer. Oligomers larger than dimers
emerge through a combination of ectodomain−ectodomain
and kinase−kinase interactions. Significantly, in agreement with
our new experimental observations, the model predicts that
Grb2 associates predominantly with EGFR tetramers. We
conclude that ligand-induced EGFR tetramers can play an
important role in sequestering Grb2, Grb2-associated proteins,
and possibly other proteins that directly interact with
phosphorylated EGFR.
■ EXPERIMENTAL PROCEDURES
Construction of Grb2−mRFP Plasmid. Human Grb2
(growth factor receptor-bound protein-2) transcript variant 1,
as 10 μg of transfection-ready DNA, was purchased from
OriGene (catalog no. SC111933) in the vector pCMV6-XL5.
Grb2 was amplified from the Origene clone using the
Invitrogen Pfx kit according to manufacturer’s instructions
with the following primers: forward 5′ GGA TAC GTA GGG
TGG CAT TGT GTG TCC CAG (incorporating a SnaB1 site)
and reverse 5′ TGA GAC GTT CCG GTT CAC GGG GGT
GAC ATA. The PCR product was purified and cloned into
pPCRScript Amp, and resulting clones were sequenced. A
correct forward-orientation clone was then cloned into
pMonoRed using HindIII and SacII. Positive clones were
identified by analytical restriction enzyme digest and then
confirmed with sequencing. Grb2-pMonoRed was further
subcloned into pBABE, a puromycin vector. The fragment
was amplified by PCR using the same forward primer as was
used previously and the reverse primer 5′ TGA GTC GAC
TTA GGC GCC GGT GGA GTG GCG. A band of the correct
size was excised from an agarose gel and purified used a
QIAGEN gel extraction kit per the manufacturer’s instructions.
Both pBABE and the PCR fragment were digested with Sal1
and SnaB1, ligated, and transformed. The resulting Grb2−
RFP−pBABE clones were confirmed by analytical digests and
sequencing.
Cells and Reagents. The murine hemopoietic cell line
BaF/3 expressing C-terminally tagged EGFR−eGFP constructs
has been described previously.8 BaF/3 cells expressing EGFR−
eGFP and mRFP−Grb2 were produced by cotransfection of
EGFR−eGFP and mRFP−Grb2 plasmids. Murine EGF was
purified from mouse submaxillary glands as described
previously.30
Live-Cell Microscopy. Suitable clones of BaF/3 cells
(transfected with EGFR−eGFP or cotransfected with EGFR−
eGFP and mRFP−Grb2) were selected using flow cytometry as
described previously.8 Cells from each clone were collected by
centrifugation (5 mL culture, 1400 rpm, 4 min, 4 °C), serum
starved for 3 h at 37 °C in serum-free medium, and then
resuspended in PBS containing 0.25% BSA and 10 μM phenyl
arsine oxide (to block receptor internalization7−9). Half of the
cell suspension was treated with EGF (final concentration: 16
nM) and half with an equivalent volume of buffer. After 20 min,
the cells were aliquoted onto a coverslip of an inverted chamber
(ambient conditions, ca. 23 °C) and imaged with a frequency-
domain lifetime-imaging microscope (100× NA1.2 oil
objective, 470 nm LED, FITC filter block, Nikon TE2000U
microscope; Nikon Inc., Japan) coupled to a LIFA lifetime
attachment (Lambert Instruments, The Netherlands). Lifetime
images were corrected for instrument response (pixel-depend-
ent instrument phase and modulation) with a solution of
rhodamine 6G in distilled water (lifetime: 4.1 ns).31 BaF/3 cells
(nontransfected) were also measured to determine the lifetime
characteristics of cell background fluorescence.
■ DATA ANALYSIS
FLIM. An intensity threshold was applied to isolate the
fluorescence from the BaF/3 cells. The fluorescence lifetime
measurements were represented in two different ways. First, to
get an indication of trends, the average phase lifetime and
average modulation lifetime were determined for each BaF/3
cell along with the average values for a number of cells. The
second approach utilized the AB plot28 (also referred to as
phasor27 or polar plot29) to display the lifetime experiments
graphically. This plot represents an experiment by a point in 2D
space defined by x = m cos φ and y = m sin φ (where φ is the
phase and m is the modulation of the fluorescence signal). This
graphical approach has the advantage that the type of
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fluorescence decay (simple, complex, or excited-state reaction/
solvent relaxation) and the complexity of the system trajectory
(binary or more complex) can be deduced visually without
further analysis. The phasor of single-exponential-decaying
fluorophores lies on a semicircle described by m = cos φ that
intersects with points (0,0), (0.5,0.5) and (1,0). Phasors from
heterogeneous fluorescence decays lie in the region within the
semicircle and follow the inequality m < cos φ. The linear
combination of two phasors is described by a linear trajectory in
AB space. This enables the distinction between optical mixing
of two species and FRET to be made.
FRET−FLIM−ICS with Two Species. The FRET−FLIM−
ICS procedure for two species was outlined in two previous
publications.9,17 In essence, three images (phase, modulation,
and intensity) are converted into two images: one that
represents the spatial intensity distribution from the FRET
species and the other the image of the non-FRET species.
For a given phasor, r(x,y), the fractional fluorescence from
the FRET states, f FRET, is given by
= | − |
| − |
f
r x y r x y
r x y r x y
( , ) ( , )
( , ) ( , )FRET
NFRET
FRET NFRET (1)
where r(x,y)NFRET is the (constant) phasor for the non-FRET
state and r(x,y)FRET is the (constant) phasor for the FRET state.
These phasor values are fixed and determined using global
analysis procedures as outlined.27,28
The fluorescence of the FRET species, IFRET, is a function of
the total intensity, ITOT, and the fractional fluorescence
resulting from the FRET species, f FRET, according to eq 1,
=I f IFRET FRET TOT (2)
A similar relationship pertains to the non-FRET species,
INON‑FRET
= −‐I f I(1 )NON FRET FRET TOT (3)
Applying eqs 1−3 to each pixel enables fluorescence images
of FRET and non-FRET states to be produced. Image
correlation spectroscopy techniques are then applied to the
fluorescence images representing the FRET and non-FRET
species.
The density of clusters (number of FRET clusters per beam
area) containing molecules undergoing FRET is given by the














If the expression level of receptors is known, then the
brightness or oligomeric state of the FRET and non-FRET



















A more robust measure, which does not require knowledge
of expression level, is the brightness ratio or BR, which is a
function of the measured cluster densities (CDFRET and
CDNFRET), fractional FRET fluorescence ( f FRET), and lifetimes
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where fraction/(1 − fraction) is equal to τNFRET f FRET/τFRET(1
− f FRET).
The brightness ratio is a particularly useful index if there is a
correlation between the occurrence of FRET and oligomeriza-
tion or dissociation. BR = 1 implies no correlation between
FRET and oligomeric state, BR > 1 implies oligomerization is
linked to FRET, and BR < 1 implies that the lower-order
oligomers are associated with FRET.
FRET−FLIM−ICS with Three Species. The total phasor
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The symbols have been defined above (see eq 1) and r(x,y)BK
represents the phasor for the background fluorescence.
Subtracting the background phasor from both sides we have
− = −
+ −
r x y r x y f r x y r x y
f r x y r x y
( , ) ( , ) ( ( , ) ( , ) )
( ( , ) ( , ) )
BK FRET FRET BK
NFRET NFRET BK
(10)
Similar to the two-species case, the phasor values are fixed,
and NFRET and BK can be determined from cells containing
donor-only and untransfected cells, respectively. The FRET
phasor can be determined using global analysis methods using
the approaches previously described.27,28 By inversion of eq 10
(using the cosine and sine components of the phasor), the
fractional fluorescence contributions from FRET and NFRET
can be extracted. Using the values of f FRET and f NFRET, the
procedures outlined for the two-species case can then be
followed.
Geometric Transformation of Phasor Approach. If the
components of the non-FRET, background, and FRET phasor
values are known, then eq 10 can be solved exactly to yield the
fraction of three species (i.e., two equations and two
unknowns). An alternative procedure based on the linear
properties of the phasor representation itself can be utilized that
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essentially subtracts the contributions from the background and
non-FRET states without explicit knowledge of the FRET
values. The steps required to achieve this are (i) to add a
constant phase to all pixels in the phase image Δ = (π/2 −
arctan((m sin φNFRET − m sin φBK)/(m cos φNFRET − m cos
φBK)), creating a new m cos(φi + Δ) image, and then (ii) to
subtract a constant value (m cos(φb + Δ)) from all pixels in the
m cos(φi + Δ) image. In essence, this rotates and translates the
phasors such that the line connecting the background and non-
FRET phasors is parallel to the y axis and intersects the origin,
making (m cos φ)NFRET and (m cos φ)BK both zero. The
transformed M cos φ image then takes the form
φ φ
φ








For a constant FRET phasor value ((m cos(φ + Δ)FRET), the
transformed M cos φ is proportional to f FRET, which is the
fraction FRET species in the pixel. Because of this
proportionality, knowledge of the actual FRET phasor value
is not required for the subsequent ICS analysis.
■ MODEL
A rule-based model reported earlier25 was extended to include
one new rule for Grb2 interaction with phosphorylated EGFR
(pEGFR) (Figures 1 and 2). This rule is associated with two
rate constants and corresponding mass-action rate laws for
Grb2−pEGFR association and dissociation. The rate constants
were set at values consistent with an equilibrium dissociation
constant (0.713 μM) and a dissociation rate constant (0.31/s)
reported in the literature.33 In addition to these parameters, a
copy number for Grb2 was also introduced to the model. This
parameter was adjusted to account for the high percentage of
EGFR−eGFP bound to Grb2−mRFP observed in our
experiments. The model was formulated using BNGL; it was
simulated using BioNetGen.34 A model specification that can
be processed by BioNetGen is provided as a plain-text file in
the Supporting Information. The file includes parameter
estimates, annotation, and simulation instructions.
The model has several notable features. It includes a cyclic
EGFR tetramer and a ligand-triggered conformation change
that frees the EGFR kinase domain to participate in kinase−
kinase interactions, which are necessary for kinase activity. A
3D structural model with atomic resolution recently con-
structed by C.-S. Tung35 suggests that the EGFR tetramer
considered in the model can feasibly form. Moreover, the
model is consistent with observed negative cooperativity in
EGF binding to intact EGFR as well as positive linkage between
EGF dose and the size of EGF-induced EGFR clusters.
■ RESULTS
FRET−FLIM Studies of the Interaction of EGFR−eGFP
with Grb2−mRFP. Previously, Sorkin et al.32 used FRET
microscopy to image the association of EGFR−CFP with
Grb2−YFP in porcine aortic cells using filter-based fluores-
cence imaging. FRET is particularly sensitive to such
interactions because of the highly nonlinear dependence of
FRET rate, R, on distance, D, between donor and acceptor
labels (R is proportional to D−6 on the length scale of 1−10
nm). To quantitatively measure the interaction between
EGFR−eGFP and Grb2−mRFP in BaF/3 cells, we utilized
lifetime-detected FRET−FLIM microscopy, which enables a
robust evaluation of FRET efficiency based on the quenching of
donor lifetime in the presence of acceptor.
Table 1 summarizes the time-resolved fluorescence param-
eters obtained using frequency-domain FLIM from measure-
ments on several sets of cells. Figure 3 portrays the time-
resolved experiments in terms of a polar plot, which is also
called an AB or phasor plot.26−29
In the absence of EGF or Grb2−mRFP, the emission from
BaF/3 cells expressing EGFR−eGFP was characterized by a
phase lifetime of 2.82 ± 0.01 ns and a modulation lifetime of
2.81 ± 0.02 ns. Importantly, addition of EGF did not
appreciably affect phase or modulation of EGFR−eGFP
fluorescence (Table 1).
BaF/3 cells cotransfected with EGFR−eGFP and Grb2−
mRFP displayed perturbations to time-resolved fluorescence
that was reflected in the lifetime parameters (Table 1). The
EGFR−eGFP phase lifetime decreased from 2.82 ± 0.01 (in
the absence of Grb2−mRFP) to 2.76 ± 0.02 ns (in the
presence of Grb2−mRFP), and the modulation lifetime
increased. In the presence of both EGF and Grb2−mRFP,
the phase lifetime of EGFR−eGFP decreased further to 2.46 ±
0.01 ns, whereas the modulation lifetime remained at the value
in the presence of Grb2−mRFP.
Insight into the physical mechanisms responsible for the
observed changes is gained by inspection of the phasor plot
(Figure 3) together with the phasor components (m cos(φ), m
sin(φ)) of the time-resolved emission from the cells and
background. The position of the phasor corresponding to BaF/
3 cells containing EGFR−eGFP is close to, but not on, the
universal circle, which indicates non-exponential behavior from
the eGFP fluorophore of EGFR−eGFP (Figure 3, blue
diamond, and Table 1).27−29 As expected, EGF treatment
Figure 1. Proteins (EGF, EGFR, and Grb2), EGFR component states,
and protein−protein interfaces considered in our computational
model. The EGFR ectodomain is taken to be free or bound to
EGF. A cytoplasmic domain of EGFR, comprising the juxtamembrane
region (JM) and kinase domain, is taken to be locked (i.e., unavailable
for interaction) or freed (i.e., available for interaction). The C-terminal
tail of EGFR is taken to contain, as a simplification, a single docking
site for Grb2, which can be unphosphorylated (Y) and inactive or
phosphorylated (pY) and active.
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Figure 2. Illustration of the rules for interactions in our computational, rule-based model. The model, which captures the mass-action chemical
kinetics of the indicated interactions, consists of 16 rules, which are either reversible (and associated with two rate constants) or unidirectional (and
associated with a single rate constant). Each rule represents an interaction. The glyphs used here to represent proteins and protein components are
the same as those presented in Figure 1. Here, in illustrating a rule, we use a question mark (?) to indicate a missing protein component or
component state that is not depicted explicitly; the missing component or state is taken to have zero influence on the interaction represented by the
rule. Similarly, representation of an EGFR ectodomain by a dotted triangle is meant to indicate that the ectodomain may or may not be present in a
complex, without influence on the interaction of concern. The model is the same as that presented in our earlier report25 except that a rule for Grb2
binding to phosphorylated EGFR has been added. This rule is illustrated in the lower left box.
Biochemistry Article
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does not significantly change the phasor position of EGFR−
eGFP (second blue diamond and Table 1). However, in the
cells containing both EGFR−eGFP and Grb2−mRFP, the
phasor lies further inside the semicircle (Figure 3A, red
diamond). This change in phasor position can be explained by
fractional emission because of the cell’s background fluo-
rescence (i.e., by background mixing only). Background mixing
only (i.e., no FRET) is apparent because the background
phasor (Figure 3B, blue circle), the EGFR−eGFP phasor
(Figure 3B, blue diamond), and the EGFR−eGFP/Grb2−
mRFP phasor (Figure 3B, red diamond) are almost collinear
(Figure 3). In contrast, EGF treatment of EGFR−eGFP/
Grb2−mRFP cells moves the phasor of EGFR−eGFP/Grb2−
mRFP in a clockwise direction such that it is no longer collinear
with the background and EGFR−eGFP cell phasors (red
triangles). These results provide qualitative evidence for an
interaction between EGFR−eGFP and Grb2−mRFP after EGF
treatment.
Using the approach of Caiolfa et al.,36 we can determine
whether FRET is significant by removing the background
contribution. By drawing a line connecting the background
phasor to the observed phasor, an apparent lifetime (i.e.,
lifetime in the absence of background) can be obtained from
the intersection point of the line with the semicircle. The
apparent lifetimes calculated in this manner are listed in Table
1. This analysis yielded an EGFR−eGFP lifetime of 2.76 ± 0.03
ns in EGFR−eGFP/Grb2−mRFP cells compared with 2.82 ±
0.03 ns in cells lacking Grb2−mRFP. A Student’s t test revealed
that the difference between 2.81 and 2.76 ns was not
statistically significant at the 95% confidence interval (p >
0.1, standard error about the mean 0.03 ns, sample size = 50).
Using the same background subtraction procedure, a lifetime of
2.5 ± 0.03 ns was obtained for EGFR−eGFP in the presence of
EGF and Grb2−mRFP. A Student’s t test revealed that the
difference in apparent lifetimes (2.85 vs 2.50 ns) was highly
significant (p < 0.0001, standard error about the mean 0.03 ns,
sample size = 50). These results provide quantitative evidence
for an EGF-dependent interaction between EGFR−eGFP and
Grb2−mRFP.
To gain further insight into the interaction, we examined the
phasors of individual EGFR−eGFP/Grb2−mRFP BaF/3 cells
in the presence of EGF (Figure 4). It is apparent that some cells
have phasors that are close to the phasor of the EGFR−eGFP
Table 1. Summary of FLIM Parameters for EGFR−GFP in Living BaF/3 Cells
ligand adaptor τphase
a τmod
b m cos(φ)c m sin(φ)c Nd τe Ef
no no 2.82 2.81 0.67 0.47 48 2.82 n.a.
yes no 2.82 2.76 0.67 0.48 23 2.85 n.a.
no yes 2.67 3.26 0.64 0.43 60 2.76 0.03
yes yes 2.46 3.20 0.78 0.67 57 2.50 0.11
background 2.30 5.50 0.51 0.29 80 n.a n.a.
aLifetime calculated from the phase of the fluorescence at 40 MHz (±0.011 ns). bLifetime calculated from the modulation of the fluorescence at 40
MHz (±0.015 ns). cComponents of the cell population FLIM phasor: m represents the modulation and φ represents the phase. dNumber of cells.
eApparent lifetime calculated by subtraction of background phasor. fApparent FRET efficiency calculated as E = 1 − (apparent lifetime(donor +
adaptor)/2.8 ns).
Figure 3. FLIM data of living BaF/3 cell populations represented on a
phasor diagram. (A) Phasor diagram over a limited data range. (B)
Phasor diagram on an expanded scale. Individual data points represent
the cell-phasor components [x = m cos(φ); y = m sin(φ)] averaged
from >20 cells. Data points correspond to BaF/3 cells transfected with
EGFR−eGFP alone (blue diamond), EGFR−eGFP + EGF (second
blue diamond), EGFR−eGFP/Grb2−mRFP (red-filled diamond),
EGFR−eGFP/Grb2−mRFP + EGF (red-filled triangle), and un-
transfected control cells (blue filled circle).
Figure 4. FLIM data of individual living BaF/3 cells represented on a
phasor diagram. Data points correspond to BaF/3 cells transfected
with EGFR−eGFP alone (blue diamond), EGFR−eGFP + EGF
(second blue diamond), EGFR−eGFP/Grb2−mRFP (red-filled
diamond), EGFR−eGFP/Grb2−mRFP + EGF (red-filled triangle),
and untransfected control cells (blue filled circle). Blue solid line
denotes trajectory for mixtures of background and EGFR−eGFP. Red
line indicates trajectory for EGFR−eGFP/Grb2−mRFP FRET
complex mixing with background and EGFR−eGFP fluorescence.
Biochemistry Article
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donor. Our intepretation is that this population of cells exhibits
no or low FRET. This interpretation is supported by the fact
that these cells appear close to the line joining the EGFR−
eGFP phasor and the background phasor (Figure 4, blue line).
The other populations of cells have phasors that lie on a line
connecting background, donor, and a highly quenched
fluorescence. Using linear extrapolation28 (Figure 4, red line),
we calculate that the lifetime of the FRET state is 0.71 ± 0.03
ns. This FRET state lifetime is physically reasonable and is
similar to the 0.75 ns lifetime determined for EGFR−eGFP
interacting with Cy3-labeled antiphosphotyrosine antibodies.27
According to this interpretation, the different phasor positions
for individual cells can be explained by different proportions of
free EGFR−eGFP and EGFR−eGFP/Grb2−mRFP complexes.
This information can be used to determine whether there is a
link between EGFR cluster size and Grb2−mRFP binding.
FRET−FLIM−ICS Measurements Reveal That Grb2 Is
Associated with Higher-Order EGFR Clusters. To assess
the relative sizes of Grb2−bound versus Grb2-free EGF−
EGFR−eGFP oligomers in EGFR−eGFP/Grb2−mRFP BaF/3
cells, we used a FRET−FLIM−ICS approach that was modified
to take background fluorescence into account. Figure 5A
displays a typical fluorescence image from EGF−EGFR−
eGFP/Grb2−mRFP complexes, and Figure 5B displays the
corresponding 2D spatial autocorrelation function image. The
amplitude of the autocorrelation function is inversely related to
the cluster density of an EGF−EGFR−eGFP/Grb2−mRFP
complex (eq 4). Analogous images of the EGF−EGFR−eGFP
complexes were also obtained, and the cluster densities were
calculated (eq 5). A summary of lifetime parameters, fraction of
EGFRs undergoing FRET, cluster densities, and brightness
ratios obtained from the analysis of several cells is shown in
Table 2. The fraction FRET values are positively correlated
with the cluster density FRET values (correlation coefficient
0.81) and also positively correlated with the brightness ratio
values (correlation coefficient 0.74), implying that EGFR
clustering and Grb2 adaptor association are linked. We shall
use the data in Table 2 to extract the information on the sizes
of EGFR−Grb2 complexes.
One estimate of cluster size comes from measurement of the
cell-averaged cluster densities (Table 2 and eq 6). Grb2-bound
EGFR clusters were dispersed at an average of 11 clusters/μm2,
whereas the Grb2-free EGFR population had a spatial
organization characterized by an average cluster density of 17
clusters/μm2. Considering that on average 74% of EGFRs make
up the Grb2-bound population and 36% the unbound
population, the normalized density for 100% Grb2-bound
EGFR clusters would be 16 clusters/μm2 and 100% Grb2-free
EGFR clusters would be 63 clusters/μm2. These cluster density
estimates agree remarkably well with cluster densities
previously determined for EGFR−eGFP in BaF/3 cells,8
namely, a tetramer density of 17 clusters/μm2 and a monomer
density of 70 clusters/μm2. Accordingly, the estimated size of
clusters containing Grb2-bound EGFR would be about 4.2 ± 1
receptors/cluster and the estimated size of clusters free of Grb2
would be about 1.1 ± 0.3 receptors/cluster.
Examination of cluster densities across different cells is also
informative (Table 2). The local EGFR 2D concentration
sampled in experiments varies over a wide range (Table 2;
CDfree: 4.1−40 clusters/μm2, CDbound: 0.9−25 clusters/μm2),
with a positive correlation between increases in CDfree with
CDbound. A plot of CDbound as a function of CDfree is depicted in
Figure 5C and closely resembles a sigmoidal binding curve. In
the context of a simple local equilibrium between EGFR and
EGFR−Grb2 complexes of size N, the concentration of
EGFR−Grb2 clusters as a function of EGFR is given by a
Hill function of the form CDbound = A/(1 + ((Kd/CDfree)
(N−1)),
where A, Kd, and N are constants. Nonlinear least-squares fit to
the data (solid line, Figure 5C) revealed (N − 1) = 3.1 and
therefore N = 4.1. This result suggests that in the context of a
simple monomer/N-mer equilibrium the cluster size of the
Grb2-bound EGFR is approximately 4.
A third method of analysis utilizes a direct calculation of the
brightness ratio for each individual cell (eq 8). The brightness
ratios obtained in this manner ranged from 3.3 to 9.3, with a
cell average of 5.5 ± 1. It is difficult to determine whether the
observed range of brightness ratios represents true cell-to-cell
variation in the proportions of different oligomeric states or
errors in the determination of cluster densities and fraction
FRET values. Using the error calculation procedure from
Wiseman’s laboratory,37 we estimate that the error in the
cluster densities is approximately 10−20% about the mean
value. We take an error of 30% in the cluster density to be
Figure 5. FRET−FLIM−ICS on living BaF/3 cells cotransfected with
EGFR−eGFP and Grb2−mRFP. (A) Fluorescence image of EGFR−
eGFP/Grb2−mRFP complexes. (B) Spatial autocorrelation image of
EGFR−eGFP/Grb2−mRFP complexes. (C) Density of Grb2−mRFP-
bound EGFR−EGFP clusters as a function of the density of Grb2−
free EGFR−eGFP clusters. The solid line is fit to a Hill function
(CDbound = A/(1 + ((Kd/CDfree)
(N−1)), with N = 4.1, A = 27, and Kd =
18 clusters).
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conservative. The FRET fraction error is estimated to be 0.05.
By error propagation analysis of eq 8, the BR has a 95%
confidence interval given by BR ± (2 × 0.43)BR. It is clear that
N = 2 cannot explain the spread of BR values because it covers
the range of BR = [0.3,3.7]. In order to match to the
experimentally determined range BR = [3.3,9.3], the error in
the BR would have to be 150% of N = 2, which is unrealistic.
However, models with oligomers of higher order than dimers
can account for the data, with a BR of 4 to 5 accounting for the
majority of observed BR values.
To summarize, using the combined data from the cells
examined, we obtained an estimated average cluster size of
approximately 4 ± 1 receptors/cluster for the adaptor-bound
receptor pool. We next compare these data with our model for
receptor aggregation and adaptor binding.
Theoretical Model of Receptor Oligomerization and
Adaptor Binding. We recently presented a model for ligand
binding, higher-order receptor oligomerization, and receptor
phosphorylation that reproduced our biophysical and bio-
chemical experiments with EGFR−eGFP in BaF/3 cells.25 Key
ingredients of the model are (i) monomer−dimer equilibrium
in the absence of ligand, (ii) retention of negative cooperativity
in the ligand-binding step using features and parameters of the
model of Pike and Macdonald,38 (iii) inclusion of a ligand-
induced conformational transition leading to liberation of the
kinase domain in the ligand-bound receptor (making it available
for interaction with a neighboring kinase domain, also in the
liberated state), (iv) receptor phosphorylation in oligomers of
size 2 or larger, (v) ectodomain and kinase domain interactions
between receptors leading to linear polymer-like aggregates up
to tetramers (i.e., dimers, trimers, and tetramers) as well as
cyclic tetramers, and (vi) phosphorylation and dephosphor-
ylation reactions.
To relate the present experimental data to models of adaptor
binding, we augmented our previous model to include a Grb2-
binding step characterized by parameters determined via
surface plasmon resonance.33 In the model, we allowed Grb2
to bind a phosphorylated receptor regardless of its aggregation
state. This aspect of the model is consistent with the
conventional view that adaptors bind exposed phosphotyrosine
residues on receptors and our experiments showing that there is
only measurable FRET between EGFR and Grb2 after EGF
stimulation. We calculated the predicted cluster size distribu-
tion of EGFR and EGFR−Grb2 complexes. Figure 6A shows
that the dominant Grb2-bound cluster is the EGFR tetramer at
all concentrations of EGF. Figure 6B displays the proportion of
each cluster bound to Grb2 from a simulation with 10 nM EGF
and parameters fixed from our previous publication. Tetramers
are the dominant species bound to Grb2, with nearly 95% of
tetramers containing at least one bound Grb2 (Figure 6B). The
trimers and dimers make up only a small fraction of the total
population (<1% of total population); however, the majority of
both the trimeric and dimeric pools do not contain any bound
Grb2 (Figure 6B). The second largest species in terms of
population is the EGFR monomer, which contributes to 28% of
the clusters. Ninety-eight percent of the EGFR monomer is not
bound to Grb2 (Figure 6B). These results agree well with the
cluster size estimates from experiments. The average value of 4
± 1 EGFR’s per EGFR−Grb2 complex from the FRET−
Table 2. Fluorescence Parameters Including Lifetime, Average Degree of Adaptor Binding, and Relative Brightness for EGF-







1 1.41 2.20 0.86 23 23 5.9
2 1.60 2.51 0.81 11 16 6.2
3 1.46 2.32 0.85 25 42 9.3
4 1.84 2.73 0.72 5.5 10 4.7
5 1.92 2.87 0.69 5.4 9.2 3.8
6 2.37 3.03 0.42 0.9 4.1 3.3
average 0.725 11.7 17.3 5.5
SEM 0.06 4 5 0.9
aLifetime calculated from the phase of the fluorescence at 40 MHz (±0.011 ns). bLifetime calculated from the modulation of the fluorescence at 40
MHz (±0.015 ns). cFraction of receptors bound to adaptor (i.e., fraction EGFR−eGFP bound to Grb2−mRFP). dCluster densities or number of
aggregates per square micrometer. The label “bound” refers to images containing only EGFR−eGFP bound to Grb2−mRFP. The label “free” refers
to images containing only EGFR−eGFP uncomplexed with Grb2−mRFP. eRelative brightness (RB) of EGFR−eGFP/Grb2−mRFP complexes
compared to uncomplexed EGFR−eGFP. Calculated from the equation RB = (fraction)g(0)bound/(1 − fraction)g(0)free
Figure 6. (A) Plot of simulation results depicting the cluster
distribution of Grb2-bound EGFR as a function of EGF concentration.
Note that at all concentrations of EGF the EGFR tetramer is the
predominant form associated with Grb2. The curves corresponding to
dimer and trimer are indistinguishable from monomer because the
total number of these oligomeric forms bound to Grb2 is almost
negligible. (B) Cluster size distribution of EGFR bound to Grb2 and
unbound (free) to Grb2 from simulation with 10 nM EGF.
Biochemistry Article
dx.doi.org/10.1021/bi500182x | Biochemistry 2014, 53, 2594−26042601
FLIM−ICS experiments is in excellent agreement with the
model prediction that the EGFR tetramer is the dominant
Grb2-bound form, whereas the dominant Grb2-free form is the
monomer, which also agrees well with the cluster size estimate
of 1 ± 0.3 EGFR’s from the cell-averaged data.
■ DISCUSSION
Alternative Interpretations. The model above assigns the
receptor clustering and adaptor binding to an oligomeric
complex formed entirely from extracellular and kinase-activated
intracellular domains of the EGFR. However, it is important to
consider the following alternative explanations of the observed
behavior:
Coated Pits. It is known that after activation EGFR is
transported to coated-pit regions of the cell membrane, where
Grb2 is also colocalized. Therefore, a trivial explanation might
be that the EGFR−Grb2 clusters we observed are multiple
copies of activated EGFR dimers that have assembled in coated
pits. For example, Nagy et al. reported pentamers of EGFR that
were associated with coated pits.39 However, there is evidence
that EGFR clusters can also form outside coated pits. First, the
measured average cluster density of the EGFR−Grb2
complexes (Table 2, CDbound = 11 clusters/μm
2) is an order
of magnitude larger than typical coated pit densities
(CDcoated‑pits = 0.5 clusters/μm
2).40 Second, high-resolution
imaging has established that EGFR nanoclusters appear outside
coated-pit regions of the cell membrane.41 Therefore, EGFR
clustering cannot be solely attributed to EGFR accumulation in
coated pits.
Subcellular Domains. Another possible explanation is that
activated EGFR dimers are corralled into subcellular domains
mediated via membrane rafts or possibly interactions with the
cytoskeleton. If we assume that after EGFR dimer activation
domain entry is a random partition process, then the domain
occupancy distribution will be a Poissonian aggregate
distribution and the equilibrium distribution between domain
and nondomain sites will be given by a simple linear partition
function. However, the CDfree versus CDbound plot (Figure 5C)
does not fit as well to a linear model as it does to a sigmoidal
Hill function; the residual sum of squares is approximately 4.6-
fold greater for the linear model than for the Hill function. We
suggest that although subcellular domains or lipid platforms
may increase local concentrations to enhance oligomerization41
our data clearly does not support a simple domain
accumulation model of activated dimers in the absence of
higher-order oligomerization.
Adaptor-Mediated Receptor Cross-Linking. It has been
reported that Sos and Grb2 can form a trimeric complex and
this trimeric Grb2−Sos−Grb2 complex can cross-link phos-
phorylated transmembrane proteins.42 Such a mechanism
might also account for the observation that Grb2-bound
EGFR is in a higher-order oligomeric complex relative to Grb2-
unbound EGFR and for the positive correlation between
Grb2−mRFP binding and EGFR−eGFP clustering. The
activated EGFR dimer has at least four phosphorylation sites
(two per receptor monomer) that recognize Grb2, allowing for
the possibility of multivalent (receptor dimer)−bivalent
(adaptor complex) interactions. Our model does not include
this adaptor-mediated cross-linking mode of interaction.
Determination of the role of adaptor-mediated receptor cross-
linking versus receptor-mediated oligomerization requires
further investigation with cells that contain defined concen-
trations of Sos, Grb2, and EGFR.
Phenyl Arsine Oxide-Mediated Phosphorylation and
Clustering. Our experiments were conducted in the presence
of phenyl arsine oxide to block receptor internalization and to
ensure that we are measuring cell-surface activation and
clustering processes. The possibility remains that the phenyl
arise oxide may influence receptor phosphorylation and
clustering by keeping receptor activity/phosphorylation at an
artificially high level. We argue that these effects are modest on
the basis of experimental and theoretical grounds. First, as
discussed in detail in our previous paper on receptor clustering
and receptor phosphorylation,25 we see negligible effects of
phenyl arise oxide on EGF-dose-dependent receptor cluster size
and phosphorylation in our BaF/3 cell system at the
concentrations of phenyl arsine oxide employed. Second, a
sensitivity analysis, performed in our earlier modeling study,25
indicates that receptor tetramer formation is insensitive to
changes in the values of the model parameters that govern
receptor phosphorylation and dephosphorylation.
Receptor clustering was recognized more than 30 years ago
as being important in the activation and biological functioning
of the EGFR.43 Notably, Schlessinger’s laboratory revealed that
the biological effects of EGF on cells could be mimicked using
bivalent or polyvalent antibodies against the receptor but not
using monovalent antibody fragments.43,44 Results from
biochemical and structural studies in noncellular environments
have produced refined models leading to the conclusion that an
asymmetric kinase dimer is required for initial kinase activation
(see refs 1, 7, and 45 for recent reviews). These studies are so
elegant that the role of the higher-order oligomers or clusters,
as distinct from the dimers, has been largely overlooked,
although oligomerization has received some notable attention
recently.7−9,20,46−52 In other cell-surface receptor systems,
receptor oligomerization or clustering, as distinct from the
initial activation event in dimers, is seriously considered as a
biological control mechanism.53−58 In this study, we examined
the possibility that the first step in the assembly of signaling
complexes at the cell membrane, the binding of adaptor to
activated receptor, might be influenced by receptor clustering.
We did this by measuring the relationship between Grb2
binding and EGFR cluster size.
The following lines of evidence point to the enhanced
propensity of higher-order oligomers of EGFR to bind the
adaptor Grb2. First, the average brightness of EGFR−eGFP
complexed with Grb2−mRFP is more than two times greater
than uncomplexed EGFR−eGFP. Because the smallest possible
aggregation state of the EGFR−eGFP is a monomer, this
implies that higher-order EGFR oligomers bind Grb2−mRFP.
Second, there is a positive correlation between fraction of
EGFR’s bound to Grb2, average cluster size, and overall
receptor density. Third, the distribution and proportion of
Grb2-bound EGFR oligomers revealed by theoretical modeling
indicated a predominance of the EGFR tetramer as the major
Grb2-bound form.
What is the significance of adaptor binding to receptor
clusters? Theoretical simulations from the Wilson/Edwards
laboratories16 revealed that Grb2 association with EGFR is
longer-lived if EGFR is clustered nonrandomly. Experimental
support for this concept also comes from single-molecule
studies that indicate a positive correlation between clustering of
phosphotyrosine binding sites and increases in dwell time of
SH2-containing proteins near the plasma membrane surface.56
To conclude, EGFR higher-order oligomers bind Grb2 and
therefore should be considered, along with the classical EGFR
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dimer, in models of EGFR signaling. Moreover, the positive
correlation between clustering of EGFR and EGFR−Grb2
interaction is consonant with the concept that the nonrandom
spatial organization of receptor dimers, in our case, tetramers,
can concentrate signaling complexes in space and time.
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